Market ExpansionFennec remains poised to reap benefits from market expansion to the adolescent and young adult (AYA) community with payor reimbursement, along with accelerating product adoption at key academic centers.
Product LaunchEuropean commercial rollout advancing with the acceptance of PEDMARQSI for use in Scotland and launches in Germany, England, and Wales.
Revenue OpportunitiesSignificant revenue opportunities remain in ex-U.S., ex-European markets where Fennec still holds the commercial rights, such as China and Japan.